Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive ...

Half-Year Results and Business UpdatePositive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC) 100% ...
Business Wire

Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its nAAVigation™ Vector Platform (nAAVigation). Leveraging decades of Adeno ...